We previously identified a 210,000-mol-wt platelet glycoprotein (GP 210) 
Introduction
Previous studies have suggested that platelet glycoprotein lb (GP lb)' functions as an Fc receptor (1, 2) . GP lb is a 170,000-molwt glycoprotein that binds von Willebrand factor (F VIII: vWF) when platelets are exposed to ristocetin (1) . In the Bernard-Soulier syndrome, platelets are deficient in GP lb and lack the ability to respond to ristocetin. Moore et al. (1) showed that binding ofaggregated IgG to platelets inhibits ristocetin-induced platelet agglutination, and suggested that the IgG complex interferes with ristocetin-induced binding ofF VIII:vWF to GP lb. Also, binding of keyhole limpet hemocyanin (KLH)-anti-KLH immune complex to platelets is blocked by prior platelet exposure to ristocetin and F VIII: vWF (2) . This observation further implicates GP lb in immune complex binding. Recently, however, Pfueller et al. (3) showed that when platelets are treated with a concentration ofchymotrypsin that hydrolyzes GP Ib, they retain their ability to bind immune complexes. This finding suggests that the Fc receptor may be distinct from GP lb. Moreover, 1 . Abbreviations used in this paper: FITC, fluorescein isothiocyanate; F VIII: vWF, von Willebrand factor; GP, glycoprotein; KLH, keyhole limpet hemocyanin; NP-40, Nonidet P40; OA, ovalbumin; TBS, Tris-buffered saline.
Cheng and Hawiger (4) isolated a 255,000-mol-wt platelet membrane glycoprotein that binds to Fc fragments immobilized on a Sepharose column.
We recently described a patient with an autoantibody directed against a 2 l0,000-mol-wt platelet membrane glycoprotein (GP 210) (5) . The F(ab)2 portion of the antibody bound to GP 210 and inhibited ristocetin-induced platelet agglutination. Also, we noted that, because heat-aggregated human IgG bound to this platelet membrane protein, the protein may have Fc receptor properties. In the present report, we have determined that GP 210 functions as an Fc receptor on platelets.
Methods
Antibody, immune complex, and Fcfragment preparations. Rabbit IgG and human IgG were prepared from serum by using Protein A-Sepharose CL6B (Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, NJ) (6). 2 mg/ml IgG was aggregated by heating at 630C for 10 min. KLH and ovalbumin (OA) were obtained from Sigma Chemical Co., St. Louis, MO. Rabbit anti-KLH was purchased from Cappel Laboratories, Malvern, PA, whereas rabbit anti-ovalbumin was obtained from Miles Scientific Div., Miles Laboratories Inc., Naperville, IL. KLH-anti-KLH and OA-anti-OA immune complexes were prepared as previously described (2) by using 2 mg/ml specific antibody for the formation of immune complex. Human Fc fragments were obtained from Dako Corp., Santa Barbara, CA, and rabbit Fc fragments were obtained from ImmunoSearch, Toms River, NJ. Human Fc fragments labeled with fluorescein isothiocyanate (FITC) were obtained from Rockland, Inc., Gilbertsville, PA. The Fc fragments were shown to be free of residual IgG by polyacrylamide gel electrophoresis (PAGE).
Serum antibody against GP 210 was obtained as previously described (5) . Rabbit anti-GP lb antibody (7) was a generous gift of Dr. Joan Fox, Gladstone Foundation Laboratories, San Francisco, CA. This antibody was raised against the glycocalicin moiety ofGP lb as previously described in detail (7) . The antibody does not react with GP Ib#, GP V, or GP IX on immunoblots (7) . 32 mg/ml ammonium sulfate-purified antibody was diluted 1:500 in Tris-buffered saline (TBS) that contained 1% gelatin (J. T. Baker Chemical Co., Phillipsburg, NJ) for use in immunoblotting. F(ab)2 from the rabbit anti-GP lb antibody was prepared as previously described (5).
solubilized platelet membranes was mixed with an equal volume of 4% SDS sample buffer in the presence or absence of 200 mM dithiothreitol. The samples were stored at -70'C until use.
Ristocetin-agglutinated platelets were prepared as follows: control platelets were separated by differential centrifugation and resuspended at 500,000/Ml in autologous platelet-poor plasma. Either 1.5 mg/ml ristocetin (Pacific Hemostasis, Bakersfield, CA) or saline buffer was added, and platelet agglutination proceeded at 370C for 10 min. Agglutination was determined by platelet aggregometry and was seen only in the ristocetin-treated sample and not in the saline control. The platelets were then washed and solubilized in the same manner as fresh platelets.
Immunoblotting. Immunoblotting studies were performed as previously described (5 Blocking experiments were carried out as follows: the nitrocellulose membranes were incubated with 2 mg/ml human or rabbit Fc fragments diluted 1:100 in TBS-1% gelatin for 1 h at room temperature. The membranes were then washed and incubated with anti-GP 210 antibody or immune complex for 2 h as described above. Rabbit Fc was used to block human antibody, whereas human Fc was used to block the rabbit immune complexes. However, neither of the Fc preparations could be visualized directly on the nitrocellulose by using the goat anti-immunoglobulin reagents, since these reagents bound primarily to intact IgG and not to Fc fragments.
Flow cytometry. Competitive binding of immune complexes and Fc fragments to intact platelets was studied by using a flow cytometric technique, as previously described (10) . In the first set of experiments, 2 X 108/ml washed control platelets were fixed with 1% paraformaldehyde and incubated with control buffer, 2 mg/ml monomeric rabbit IgG, 2 mg/ml heat-aggregated rabbit IgG, or 2 mg/ml rabbit Fc fragments for 30 min at room temperature. The platelets were then washed and incubated with 2 mg/ml human anti-GP 210 antibody for 30 min at room temperature. Binding of the human antibody, which does not crossreact with rabbit IgG, was detected by using biotinylated goat F(ab)2 directed against human IgG (Tago Inc.). The platelets were then incubated with avidin linked to FITC (Tago Inc.) and analyzed in a flow cytometer. Binding of anti-GP 210 antibody was expressed as mean platelet fluorescence on a logarithmic scale. Inhibition of binding was expressed as the percent decrease in mean fluorescence that was induced by preincubation with immune complex or Fc fragments as compared with baseline binding of anti-GP 210 to the fixed platelets.
In the second set of experiments, paraformaldehyde-fixed platelets were incubated with serum, 2 mg/ml F(ab)2 fragments, or 2 mg/ml unlabeled human Fc fragments for 30 min at 37°C. The platelets were then washed and incubated with 2 mg/ml FITC-labeled human Fc fragments for 30 min at 37°C. Fc binding to platelets was expressed as mean platelet fluorescence, as measured by flow cytometry. Inhibition of Fc binding was expressed as the percent decrease in mean fluorescence induced by serum, F(ab)2 fragments, or unlabeled Fc fragments compared to controls. Experiments were performed in duplicate on separate occasions using two different platelet donors.
Results
Figs. 1 and 2 demonstrate the effects of chymotrypsin and ristocetin on platelet GP lb and GP 210 by using antibodies against these antigens. Fig. 1 shows that rabbit antiserum against GP Ib, bound to several membrane components in control platelets (Fig. 1, lane A) : a major 170,000-mol-wt band corresponding to GP Ib, and a 210,000-260,000-mol-wt broad nonhomogeneous complex. In Bernard-Soulier platelets, which are known to be deficient in GP Ib, binding to the 170,000-mol-wt protein was not seen (Fig. 1, lane B) . Also, the antibody failed to bind to the lower portion of the 210,000-260,000-mol-wt complex. Chymotrypsin-treated platelets in which GP lb was cleaved retained the entire 210,000-260,000-mol-wt complex (Fig. 1 , lane C). Platelets exposed to ristocetin reacted with anti-GP lb (Fig. 1 , lane D), but immunoreactivity of the lower portion of the 210,000-260,000-mol-wt complex was diminished. Platelets treated only with aggregation buffer (Fig. 1 , lane E) appeared no different than control platelets (Fig. 1, lane A) .
Binding of anti-GP 210 antibody to the same platelet preparations is shown in Fig. 2 . Antibody to GP 210 bound to control platelets (lanes A and E) and chymotrypsin-treated platelets (lane C), but not to Bernard-Soulier platelets (lane B) or ristocetintreated platelets (lane D). Thus, GP 210 was deficient in BernardSoulier platelets that also lacked GP lb (Fig. 1, lane B) , and was no longer immunologically detectable after exposure ofplatelets to ristocetin, although GP lb remained intact (Fig. 1, lane D) . This finding suggests that GP 210 was altered after exposure of platelets to ristocetin; however, we could not detect GP 210 by immunoblotting in the plasma supernatant after ristocetin-induced platelet agglutination (data not shown). Fig. 3 shows binding ofimmune complexes to control platelet proteins that were transferred to nitrocellulose. 2 Fig. 1 ), but GP 210 appeared to be altered or lost, since immune complex no longer bound to it. Platelets treated only with aggregation buffer (lane E) bound KLH-anti-KLH in the same manner as control platelets (lane A). ments (bar C). 2 mg/ml monomeric rabbit IgG failed to block binding of anti-GP 210 to the intact platelets (data not shown).
In Fig. 8 , binding of FITC-labeled Fc fragments was measured after preincubation of platelets with serum ( Fig. 8 A) or F(ab)2 and unlabeled Fc fragments (Fig. 8 B) . Anti-GP 210 antiserum or F(ab)2 fragments inhibited Fc binding to platelets by 70-75%. Preincubation of platelets with control serum, control F(ab)2 fragments, and serum or F(ab)2 fragments from another patient with anti-platelet antibody failed to inhibit Fc binding. Our results also demonstrate the importance of the solubilizing detergent in determining the molecular weight of membrane proteins that are separated by SDS-PAGE, as suggested by Metzger and his colleagues (18, 19) . In a recent study, Rosenfeld et al. (20) incubated a mouse monoclonal anti-Fc receptor antibody with radiolabeled NP-40-solubilized platelets. This antibody immunoprecipitated a 40,000-mol-wt platelet protein in the presence of NP-40. We have now shown that human anti-GP 210 antibody binds to a similar molecular weight protein in NP-40-solubilized platelets that were subjected to immunoblotting (Fig. 5) . Thus, GP 210 may represent a complex between a large membrane protein and a lower molecular weight Fc receptor. An analogous membrane complex that is composed ofthree proteins has been identified as the IgE receptor on human mast cells (19) .
Our current findings suggest a structural and/or functional relationship between GP 210 and GP lb. Previously we showed that an autoantibody against GP 210 blocks ristocetin-induced platelet agglutination by F VIII:vWF (5). Kunicki et al. (21) and Nachman et al. (22) have shown that a 2 10,000-mol-wt platelet membrane glycoprotein copurifies with GP lb on wheat germ affinity chromatography; thus, GP 210 may be associated with GP lb in the platelet membrane. Binding ofimmune complexes to GP 210 may therefore sterically hinder interaction of GP lb with ristocetin or F VIII:vWF and block aggregation. This mechanism would explain the findings of Moore et al. (1) . Although Nachman et al. (22) suggested a structural similarity between GP 210 and GP lb based on tryptic peptide mapping, the exact nature ofGP 210 and its relationship to GP lb remains unknown. Selective chymotrypsin-induced cleavage of GP lb and not GP 210 in intact platelets suggests that GP 210 is anatomically distinct from GP lb in the platelet membrane. However, the possibility that GP 210 represents a complex between 1 70,000-mol-wt GP lb and the 40,000-mol-wt Fc receptor described by Rosenfeld et al. (20) has not been excluded.
In summary, we have shown that GP 210 serves as an Fc receptor on platelets. GP 210 is functionally distinct from GP Ib, which explains why selective loss of GP lb does not abolish immune complex binding to platelets. In contrast, absence of GP 210 in Bernard-Soulier platelets and its alteration after exposure of normal platelets to ristocetin may explain the failure ofimmune complexes to bind to these platelets. The composition ofGP 210 and its relationship to GP lb in the platelet membrane remain to be determined.
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